HealthcareServices

Global Chronic Sialorrhea Market Trends and Growth Analysis 2025–2029

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Chronic Sialorrhea Market Over The Five-Year Period 2025–2029?

The chronic sialorrhea market has demonstrated significant expansion in recent years. Projections indicate it will rise from $0.72 billion in 2024 to $0.76 billion in 2025, at a compound annual growth rate (CAGR) of 6.2%. The historical growth in this market can be linked to factors such as the increasing prevalence of neurological disorders, an increase in population, the increasing prevalence of neurological disorders, rising awareness and diagnosis, and an increase in demand for non-invasive treatments.

The chronic sialorrhea market size is projected to experience substantial growth in the next few years. It is anticipated to expand to $0.97 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.1%. This expansion during the forecast period is driven by increasing awareness of treatment options, a growing need for effective therapeutic solutions, rising healthcare expenditure, an increase in pediatric cases, and a surging demand for oral gels and liquid. Prominent trends expected in this period include the utilization of telemedicine for remote monitoring, the adoption of patient-centered care models, advancements in pharmacology, the integration of speech and occupational therapies, and the development of long-acting pharmaceuticals.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21149&type=smp

Which Factors And Drivers Are Influencing The Chronic Sialorrhea Market In 2025?

The chronic sialorrhea market is poised for growth, driven by the increasing incidence of neurodegenerative disorders. These disorders are defined as a category of illnesses marked by the progressive breakdown or death of nerve cells (neurons) within the brain and spinal cord. The surge in neurodegenerative disorders stems from factors such as genetic predisposition, environmental influences, an improved understanding of disease mechanisms, chronic health issues, and socio-psychological elements. Chronic sialorrhea frequently arises as a complication of neurodegenerative disorders, including Parkinson’s disease and ALS, necessitating targeted therapies to prevent aspiration, improve oral function, and enhance patient comfort. As an illustration, in September 2023, Parkinson’s UK, a UK-based charitable company, reported that approximately 153,000 individuals in the UK are currently living with Parkinson’s, with this number projected to increase by 20% to an estimated 172,000 by 2030, influenced by an aging population. Therefore, the rising prevalence of neurodegenerative disorders will act as a significant driver for the expansion of the chronic sialorrhea market.

Which Key Segments Fueling The Chronic Sialorrhea Market?

The chronic sialorrheamarket covered in this report is segmented –

1) By Treatment Type: Pharmacological Treatments; Botulinum Toxin Injections; Surgical Interventions; Medical Devices And Assistive Therapies

2) By Route Of Administration: Oral Medications; Injectable Treatments; Topical Applications

3) By Patient Population: Pediatric Patients; Adult Patients

4) By End-User: Hospitals And Specialty Clinics; Rehabilitation Centers; Homecare Settings

Subsegments:

1) By Pharmacological Treatments: Anticholinergic Medications; Antidepressants; Alpha-adrenergic Agonists; Salivary Gland Modulators

2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox); Botulinum Toxin Type B (Myobloc); Localized Salivary Gland Injections

3) By Surgical Interventions: Sialendoscopy; Salivary Gland Duct Dilation or Stenting; Parotid Duct Surgery; Submandibular Gland Removal (Sialadenectomy)

4) By Medical Devices And Assistive Therapies: Oral Dryness Devices; Salivary Stimulation Devices; Lip and Mouth Exercises; Artificial Salivary Glands

Which Market Trends Are Creating New Opportunities In The Chronic Sialorrhea Industry?

Companies prominent in the chronic sialorrhea market are concentrating on developing innovative treatments, such as oral solutions, aiming to enhance patient compliance and offer non-invasive alternatives for managing chronic sialorrhea in children, thereby improving safety and effectiveness while concurrently reducing side effects. An oral solution is a liquid medication prepared for oral consumption, where the active ingredient is dissolved in a solvent, designed for simple ingestion. For example, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France, intended for the treatment of severe chronic sialorrhea in children with neurological disorders. A significant aspect of this product is its liquid composition, specifically developed for ease of administration and accurate dosing, making it particularly suitable for pediatric patients who encounter difficulties with solid medications. It presents a well-demonstrated safety and efficacy profile, assisting in the improvement of quality of life by diminishing excessive drooling, a frequent problem encountered in neurodevelopmental conditions like cerebral palsy.

Which Leading Companies Dominate The Chronic Sialorrhea Market Share?

Major companies operating in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, Solstice Neurosciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-sialorrhea-global-market-report

How Is Chronic Sialorrhea Market Demand Varying Across Different Regions?

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic sialorrhea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Sialorrhea Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21149&type=smp

Browse Through More Reports Similar to the Global Chronic Sialorrhea Market 2025, By The Business Research Company

Chronic Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Disease Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795